TC BioPharm (Holdings) plc - American Depositary Shares (TCBP)

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

TC BioPharm said its securities will be suspended for trading on the exchange beginning Monday.

TC Biopharm shares are trading lower by 64% during Friday's session. The company announced the transition from Nasdaq to OTC markets.

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech company focused on allogeneic gamma-delta T cell therapies, announced it will be delisted from the Nasdaq Stock Market following a determination by the Nasdaq Hearings Panel. The decision, dated March 20, 2025, stems from the company’s failure to meet the minimum $1.00 bid price required under Rule 5550(a)(2). Trading on Nasdaq will be suspended at the opening on March 24, and the company expects its American Depositary Shares to begin trading on the OTC Markets the same day. TC BioPharm stated it is appealing the decision and affirmed its ongoing commitment to research and development.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, is implementing a strategic shift to a decentralized model, outsourcing key functions to contract development and manufacturing organizations (CDMOs). The transition is expected to reduce operational costs by approximately 55% compared to 2024, with estimated annual savings of $4.2 million. As part of this restructuring, the company will reduce its workforce by around 20 employees, primarily in production and quality divisions. CEO Bryan Kobel emphasized that the move positions TC BioPharm for future clinical trials and advancements in cell therapy manufacturing.

TC BioPharm (NASDAQ: TCBP) a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company specializing in glaucoma and ocular hypertension treatments. The acquisition target has an FDA-approved once-daily eye drop and a pipeline of ophthalmology assets, with a commercial launch expected to drive revenue growth in 2025. TC BioPharm plans to finalize a binding agreement in the coming weeks and complete the all-stock transaction in the third quarter of 2025, expanding its portfolio into new therapeutic areas.

TC BioPharm (NASDAQ: TCBP) announced that CEO Bryan Kobel will participate in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum on Feb. 27 at 1:10 p.m. CET in Zurich. The forum, set for Feb. 26-27 at the Hilton Zurich Airport Hotel, will feature discussions on AI, diagnostics, and health technology, with over 12 hours of keynotes and panels on industry advancements.

TC BioPharm (NASDAQ: TCBP) announced the completion of patient dosing in Cohort A of its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for relapsed or refractory acute myeloid leukemia (AML). Early data indicate a favorable safety profile, with no drug-related adverse events, and show multiple patients achieving stable disease following treatment. Recruitment into Cohort B remains ongoing as the company refines its clinical strategy for TCB008, including its potential as a bridge to transplant or in combination therapies.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

TC BioPharm (NASDAQ: TCBP) has completed full dosing for the first Cohort B patient in its Phase 2B ACHIEVE clinical trial evaluating TCB008 for acute myeloid leukemia (AML) in the UK. The study, assessing the therapy’s safety and efficacy, has shown no drug-related adverse events. Recruitment for Cohort B, which includes patients in remission with minimal residual disease, began ahead of schedule in late 2024, with enrollment for a second patient underway. CEO Bryan Kobel highlighted the therapy’s potential for AML patients facing limited treatment options, with full cohort enrollment expected in the first half of 2025 and data readout later this year.

TC BioPharm's Phase 2B trial of TCB008 in AML progresses as the first Cohort B patient completes dosing. Enrollment continues, with data expected in 2025.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company, announced a change in the ratio of its American Depositary Shares (“ADSs”) to ordinary shares from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares, effective Feb. 10, 2025. The adjustment will function as a 1-for-20 reverse ADS split but will not affect the total number of underlying ordinary shares. The Bank of New York Mellon, the company’s depositary bank, will manage the exchange, with fractional entitlements aggregated and sold, and proceeds distributed to holders. TC BioPharm expects the ADS trading price to rise proportionally but does not guarantee specific price outcomes.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, TCB008, targeting H5N1 “bird flu.” TCB008 is an allogeneic gamma delta T cell therapy designed to leverage the immune system against infections like H5N1, which recently caused the first reported U.S. fatality in Louisiana. TC BioPharm aims to collaborate with leading infectious disease centers or universities to expedite studies and prepare for a Phase I trial. CEO Bryan Kobel emphasized TCB008’s potential in addressing infectious diseases, underscoring the company’s commitment to combating emerging health threats.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, announced that CEO Bryan Kobel will present a corporate overview at the Sequire Investor Summit 2025. The conference will take place Jan. 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech company focused on gamma-delta T cell therapies for cancer, announced that its American Depository Shares remain actively traded on the Nasdaq Global Select Market under the ticker symbol “TCBP.” The company clarified that there has been no trading halt and that shares are expected to trade without interruption. This announcement does not constitute any offer or solicitation regarding securities transactions.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on gamma-delta T cell therapies, announced shareholder approval of a 25% special stock dividend. Shareholders of record as of Jan. 2, 2025, will receive 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held, with distribution expected around January 6, 2025. CEO Bryan Kobel emphasized the dividend as a reflection of confidence in the company’s financial outlook and a strategic move to enhance shareholder value. Nasdaq trading of TCBP ADSs will pause temporarily from January 2 to January 8 to facilitate the dividend process.

TC BioPharm (NASDAQ: TCBP) announced encouraging progress in its ACHIEVE Phase 2b trial in the UK, with three patients completing the full-dose regimen of TCB008 with no drug-related adverse events. The trial, evaluating TCB008 for AML and MDS/AML, has enrolled 10 patients so far, with nine receiving their second dose, four their third dose, and three their final dose. Preliminary safety data indicates the 5mL dose is well-tolerated, supporting the study’s safety objectives. Recruitment has advanced swiftly, with nine of 14 planned patients for Cohort A (relapsed/refractory disease) and one for Cohort B (minimal residual disease) enrolled. Company executives noted the trial’s rapid progress and the potential for expedited review in Cohort B, as the team focuses on completing recruitment and data analysis in 2025.